Do certain patients get better joint pain relief from Cosentyx?
Cosentyx (secukinumab), an IL-17A inhibitor, provides joint pain relief in psoriatic arthritis (PsA) and ankylosing spondylitis (AS) patients, with greater benefits seen in those with higher baseline disease activity. In PsA trials, patients with more severe joint involvement (e.g., higher DAS28 scores) achieved faster and higher rates of pain reduction, with 60-70% reporting at least 30% improvement by week 24 versus 20-30% on placebo.[1][2]
Which PsA subtypes respond best?
Patients with polyarticular PsA (5+ tender/swollen joints) show stronger responses. Phase 3 FUTURE studies found cosentyx reduced joint pain by 50-60% in these groups at week 52, outperforming those with oligoarticular disease (2-4 joints), where relief averaged 40%.[1] Enthesitis-dominant PsA also benefits, with 50-70% resolution rates versus 20% placebo.[2]
How does it perform in ankylosing spondylitis for pain?
In AS, cosentyx excels in patients with high CRP levels (>1 mg/L) or elevated baseline pain scores (>60/100 mm VAS). MEASURE trials showed these groups had 2-3 times higher odds of 50% pain reduction at week 16 (OR 3.5-5.0) compared to low-CRP patients.[3] HLA-B27 positive status correlates with better outcomes, though not exclusively.
What about patients who've failed other biologics?
Switchers from TNF inhibitors gain substantial relief: 45-55% achieve minimal disease activity in joints/pain after prior TNF failure, per MAXIMISE trial data, versus 25% continuing TNFs.[4] This holds for both PsA and AS.
Age, gender, or comorbidity factors?
Younger patients (<45 years) and males report modestly faster pain relief (1-2 weeks earlier onset).[1][3] Those with comorbidities like obesity (BMI >30) see reduced efficacy—30-40% less pain improvement—likely due to inflammation barriers.[2] No major differences by gender overall.
[1]: Cosentyx PsA Pivotal Trials (Novartis data)
[2]: Mease PJ et al. FUTURE 5 Study. Lancet 2018.
[3]: Baraliakos X et al. MEASURE 1/2. Ann Rheum Dis 2017.
[4]: Nash P et al. MAXIMISE Trial. Lancet 2021.